Qnovia

Richmond, United States Founded: 2018 • Age: 8 yrs
Inhaled drug delivery devices are developed for pharmaceuticals.
Request Access

About Qnovia

Qnovia is a company based in Richmond (United States) founded in 2018 by Mario Danek.. Qnovia has raised $38.12 million across 4 funding rounds from investors including Blue Ledge Capital, Evolution VC Partners and Vice Ventures. Qnovia offers products and services including Inhaled Drug Delivery Platform. Qnovia operates in a competitive market with competitors including MannKind Corp, OptiNose, Impel NeuroPharma, Alexza and Iconovo, among others.

  • Headquarter Richmond, United States
  • Founders Mario Danek
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Qnovia, Inc.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $38.12 M (USD)

    in 4 rounds

  • Latest Funding Round
    $16 M (USD), Series B

    Oct 29, 2024

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Qnovia

Qnovia offers a comprehensive portfolio of products and services, including Inhaled Drug Delivery Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Technology for optimizing pharmaceutical delivery via inhalation to improve outcomes.

People of Qnovia
Headcount 1-10
Employee Profiles 4
Employee Profiles
People
Chris C.
Chief Science Officer
People
Joe Walsh
Head of Product

Unlock access to complete

Funding Insights of Qnovia

Qnovia has successfully raised a total of $38.12M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $16 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Series B — $16.0M
  • First Round

    (13 Jan 2020)

  • Investors Count 6
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2024 Amount Series B - Qnovia Valuation Blue Ledge Capital , Evolution VC Partners
Jun, 2023 Amount Series A - Qnovia Valuation

investors

Sep, 2022 Amount Series A - Qnovia Valuation Blue Ledge Capital
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Qnovia

Qnovia has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Blue Ledge Capital, Evolution VC Partners and Vice Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investments in tech startups are made by Evolution VC Partners.
Founded Year Domain Location
Early stage venture capital fund focused on stigmatized industries is operated.
Founded Year Domain Location
Venture capital investing with a focus on diversity and inclusion in the ecosystem.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Qnovia

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Qnovia

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Qnovia Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Qnovia

Qnovia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, OptiNose, Impel NeuroPharma, Alexza and Iconovo, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of small-molecule drugs
domain founded_year HQ Location
Developer of smart devices for nasal drug delivery
domain founded_year HQ Location
Intranasal delivery technology for CNS diseases is developed.
domain founded_year HQ Location
Developer of products for the treatment of acute and intermittent conditions
domain founded_year HQ Location
Inhalation devices for medical applications are developed by Iconovo.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Qnovia

Frequently Asked Questions about Qnovia

When was Qnovia founded?

Qnovia was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Qnovia located?

Qnovia is headquartered in Richmond, United States. It is registered at Richmond, Virginia, United States.

Is Qnovia a funded company?

Qnovia is a funded company, having raised a total of $38.12M across 4 funding rounds to date. The company's 1st funding round was a Series A of $17M, raised on Jan 13, 2020.

What does Qnovia do?

Qnovia was founded in 2018 and is based in Richmond, United States. Inhaled drug delivery devices are developed by the company for a broad range of pharmaceuticals within the medtech sector. Operations focus on products such as RespiRx, a combination drug for inhalable nicotine replacement therapy aimed at smoking cessation, and a vibrating mesh nebulizer designed for lung-targeted delivery.

Who are the top competitors of Qnovia?

Qnovia's top competitors include MannKind Corp, OptiNose and Impel NeuroPharma.

What products or services does Qnovia offer?

Qnovia offers Inhaled Drug Delivery Platform.

Who are Qnovia's investors?

Qnovia has 6 investors. Key investors include Blue Ledge Capital, Evolution VC Partners, Vice Ventures, Gaingels, and DG Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available